Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug;18(2):1579-1584.
doi: 10.3892/ol.2019.10485. Epub 2019 Jun 18.

Metabolic reprogramming and its clinical application in thyroid cancer

Affiliations
Review

Metabolic reprogramming and its clinical application in thyroid cancer

Shi-Shuai Wen et al. Oncol Lett. 2019 Aug.

Abstract

Warburg found that tumor cells exhibit high-level glycolysis, even under aerobic condition, which is known as the 'Warburg effect'. As systemic changes in the entire metabolic network are gradually revealed, it is recognized that metabolic reprogramming has gone far beyond the imagination of Warburg. Metabolic reprogramming involves an active change in cancer cells to adapt to their biological characteristics. Thyroid cancer is a common endocrine malignant tumor whose metabolic characteristics have been studied in recent years. Some drugs targeting tumor metabolism are under clinical trial. This article reviews the metabolic changes and mechanisms in thyroid cancer, aiming to find metabolic-related molecules that could be potential markers to predict prognosis and metabolic pathways, or could serve as therapeutic targets. Our review indicates that knowledge in metabolic alteration has potential contributions in the diagnosis, treatment and prognostic evaluation of thyroid cancer, but further studies are needed for verification as well.

Keywords: metabolism; predictive factor; prognosis; targeted therapy; thyroid cancer.

PubMed Disclaimer

References

    1. Wiltshire JJ, Drake TM, Uttley L, Balasubramanian SP. Systematic Review of Trends in the Incidence Rates of Thyroid Cancer. Thyroid. 2016;26:1541–1552. doi: 10.1089/thy.2016.0100. - DOI - PubMed
    1. Navas-Carrillo D, Ríos A, Rodríguez JM, Parrilla P, Orenes-Piñero E. Familial nonmedullary thyroid cancer: Screening, clinical, molecular and genetic findings. Biochim Biophys Acta. 2014;1846:468–476. - PubMed
    1. Jillard CL, Scheri RP, Sosa JA. What is the optimal treatment of papillary thyroid cancer? Adv Surg. 2015;49:79–93. doi: 10.1016/j.yasu.2015.03.007. - DOI - PubMed
    1. Pacini F, Cetani F, Miccoli P, Mancusi F, Ceccarelli C, Lippi F, Martino E, Pinchera A. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg. 1994;18:600–604. doi: 10.1007/BF00353775. - DOI - PubMed
    1. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: Implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 2008;8:83–95. doi: 10.1586/14737159.8.1.83. - DOI - PubMed